Extending the reach of BRAF-targeted cancer therapy

Lancet. 2012 May 19;379(9829):1858-9. doi: 10.1016/S0140-6736(12)60610-2.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Female
  • Humans
  • Imidazoles / administration & dosage*
  • Male
  • Neoplasms / drug therapy*
  • Oximes / administration & dosage*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Oximes
  • Proto-Oncogene Proteins B-raf
  • dabrafenib